20,778 Shares in Pfizer Inc. (NYSE:PFE) Acquired by denkapparat Operations GmbH

denkapparat Operations GmbH purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 20,778 shares of the biopharmaceutical company’s stock, valued at approximately $551,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. United Bank boosted its stake in Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 1,277 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Pfizer by 67.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company’s stock valued at $428,000 after purchasing an additional 5,959 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in Pfizer by 7.3% during the third quarter. Loomis Sayles & Co. L P now owns 8,450 shares of the biopharmaceutical company’s stock worth $245,000 after acquiring an additional 577 shares during the last quarter. FMR LLC raised its position in shares of Pfizer by 3.1% in the third quarter. FMR LLC now owns 14,478,489 shares of the biopharmaceutical company’s stock valued at $419,007,000 after buying an additional 435,311 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Pfizer in the 3rd quarter valued at $1,685,000. 68.36% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Trading Down 0.6 %

Shares of PFE stock opened at $25.05 on Friday. The stock has a market cap of $142.08 billion, a price-to-earnings ratio of 17.77, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The firm has a fifty day moving average of $26.09 and a 200-day moving average of $26.97.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the firm posted $0.10 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.